Credit: Eton. Khindivi is expected to be available the week of June 2, 2025. Khindivi is the first FDA-approved hydrocortisone oral solution. The Food and Drug Administration (FDA) has approved ...

Khindivi is the sole FDA-approved hydrocortisone oral solution and is available in a 1mg/ml concentration. This formulation is particularly beneficial as it removes the necessity of splitting or ...

On May 28, 2025, the FDA approved Eton Pharmaceuticals' new drug application (NDA) for hydrocortisone oral solution (Khindivi) as a replacement therapy for pediatric patients aged 5 years or older ...

Eton Pharmaceuticals’ new drug application (NDA) for Khindivi, an oral solution of hydrocortisone, has received US Food and Drug Administration (FDA) approval as a replacement therapy for ...

Oral thrush, otherwise known as oral candidiasis, is a fungal infection in adults and children that is treated with antifungal drugs, most commonly in the form of lozenges and oral solutions that can ...

• KHINDIVI is the first and only FDA-approved hydrocortisone oral solution• Commercial launch expected the week of June 2nd• Eton expects combined peak sales of KHINDIVI and ALKINDI SPRINKLE ...

Common indications for the use of systemic therapy, including terbinafine, ketoconazole, itraconazole, fluconazole and griseofulvin, in children and young adults are reviewed.

Also in May, Relonchem secured the regulator's approval for Gabapentin Oral Solution, 50 mg/ml, which is prescribed to manage nerve pain and epilepsy. In March, Marksans Pharma's manufacturing ...

Terbinafine (oral/topical) or amorolfine: Lamisil (Rx) If symptoms don’t improve after a few weeks, or if the infection spreads, check with a healthcare provider for stronger or more targeted ...

The FDA has approved Khindivi (hydrocortisone) oral solution as a replacement therapy for children aged 5 years and older with adrenocortical insufficiency.This ready-to-use, berry-flavored liquid ...